QS-21 + monophosphoryl lipid A

QS-21 + monophosphoryl lipid A has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 18, 2021: “Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice”.

Intervention

1 paper studies it1 more mentions it2 findingsUpdated

PubChemPubChem

See all 2 papers on QS-21 + monophosphoryl lipid A

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Institute of Allergy and Infectious Diseases and 1 more
  • Animals1

What did studies of QS-21 + monophosphoryl lipid A find?

2

Studies of QS-21 + monophosphoryl lipid A measured 2 outcomes: weight loss and influenza.

Weight loss

downin mice1

1 study
  1. QS-21 + monophosphoryl lipid A prevents weight loss in mice (influenza vaccination).

    “Both combination adjuvants (QS-21+MPL and CpG+MPL) exhibited high potency by preventing weight loss”

    Animalsinfluenza vaccination

    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice

    Antiviral research

Influenza

downin mice1

1 study
  1. QS-21 + monophosphoryl lipid A protects against influenza in mice (influenza vaccination).

    “enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models.”

    Animalsinfluenza vaccination

    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice

    Antiviral research

More on Influenza

Latest